IART Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Integra Lifesciences Holdings Corp (IART) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive catalysts such as improved leadership, better supply chain visibility, and a growing regenerative medicine market. Despite some technical indicators being neutral, the stock's recent upgrades and raised price targets signal confidence in its recovery and growth potential.
The MACD is negative and expanding (-0.097), indicating bearish momentum. However, the RSI is neutral at 58.79, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot point (17.487), with immediate resistance at 18.077 and support at 16.896.
Leadership change with the return of Stuart Essig as CEO, boosting confidence in earnings turnaround.
Regenerative medicine market projected to grow significantly, benefiting IART's product portfolio.
Analysts upgraded the stock with raised price targets, citing improved supply and demand dynamics.
MACD indicates bearish momentum.
Competition in the regenerative medicine market remains intense, requiring strategic innovation.
No financial data available for the latest quarter, but analysts noted improved Q1 EPS and raised guidance, indicating positive growth trends.
Analysts have recently upgraded the stock. Argus upgraded it to Buy with a $25 price target, citing confidence in an earnings turnaround. Citi upgraded it to Neutral from Sell, with a price target of $16, up from $11, due to easing headwinds and better remediation visibility.
